Accuracy of AST to platelet ratio for predicting liver fibrosis in patients with chronic HCV infection after viral eradication

Background and Aims. Serum fibrosis biomarkers have shown good accuracy in the liver transplant (LT) population. We employed a simple serum biomarker to elucidate incidence and predictors of advanced fibrosis after LT over a long follow-up period.Methods. We included 440 consecutive patients who underwent LT between 1991 and 2013. Advanced liver fibrosis was defined as FIB-4 > 3.25 beyond 12 months after LT.Results. Over 2030.5 person-years (PY) of follow-up, 189 (43%) developed FIB-4 > 3.25, accounting for an incidence of 9.3/100 PY (95% confidence interval [CI], 8.1–10.7). Advanced fibrosis was predicted by chronic HCV infection (adjusted hazard ratio (aHR) = 3.96, 95% CI 2.92–5.36,p< 0.001), hypoalbuminemia (aHR = 2.31, 95% CI 1.72–3.09;p< 0.001), and hyponatremia (aHR = 1.48, 95% CI 1.09–2.01;p= 0.01). LT recipients with more than 1 predictor had a higher incidence of advanced fibrosis, the highest being when all 3 predictors coexisted (log-rank:p< 0.001).Conclusions. Chronic HCV infection, hypoalbuminemia, and hyponatremia predict progression to advanced liver fibrosis following LT. Patients with these risk factors should be serially monitored using noninvasive fibrosis biomarkers and prioritized for interventions.

Download Full-text

Non-invasive methods for the diagnosis of liver fibrosis in chronic HCV infection

Practical medicine ◽

10.32000/2072-1757-2019-8-44-47 ◽

2019 ◽

Vol 17 (8) ◽

pp. 44-47

Author(s):

A. I. Fazulzyanova ◽

◽

S. V. Tkacheva ◽

A. K. Khusainova ◽

N. F. Gayfutdinov ◽

...

Keyword(s):

Liver Fibrosis ◽

Hcv Infection ◽

Non Invasive ◽

Chronic Hcv Infection ◽

Chronic Hcv

Download Full-text

Comparison of liver biopsy and non-invasive APRI test in assessing the stage of liver fibrosis in patients with chronic HCV infection

Porto Biomedical Journal ◽

10.1016/j.pbj.2017.07.045 ◽

2017 ◽

Vol 2 (5) ◽

pp. 194

Author(s):

Nina Adzic ◽

Mirjana Arapovic

Keyword(s):

Liver Fibrosis ◽

Liver Biopsy ◽

Hcv Infection ◽

Non Invasive ◽

Chronic Hcv Infection ◽

Chronic Hcv

Download Full-text

Prevalence of comorbidity in chronic HCV‑infection

Medical alphabet ◽

10.33667/2078-5631-2021-1-66-70 ◽

2021 ◽

pp. 66-70

Author(s):

E. V. Esaulenko ◽

K. E. Novak ◽

V. V. Basina ◽

A. A. Dzemova ◽

R. A. Ganchenko

Keyword(s):

Diabetes Mellitus ◽

Gastrointestinal Tract ◽

Cardiovascular Diseases ◽

Liver Fibrosis ◽

Biliary Tract ◽

Mutual Influence ◽

Hcv Infection ◽

Occult Hepatitis ◽

Chronic Hcv Infection ◽

Chronic Hcv

The effect of the comorbid background on the course of the infectious process in chronic HCV infection requires study due to the existence of a risk of progression of liver fibrosis even after the eradication of the virus against the background of concomitant diseases.Material and methods. The article analyzes the prevalence of various comorbid conditions in 700 patients with chronic HCV infection, who were observed in the hospital of the Botkin in St. Petersburg, an assessment of the mutual influence of the comorbid background and the progression of liver fibrosis in HCV infection was given. To determine the contribution of comorbidity to the course of HCV infection, the odds ratio (OR) parameters were calculated.Results. HCV-infected individuals have higher prevalence of comorbidity (63 %) and multimorbidity (50 %). In patients with severe fibrosis or cirrhosis, the presence of the comorbidity factor increased to 85 %. In the examined group of patients, diseases of the biliary tract and pancreas prevailed (30.0 %), occult Hepatitis B Infection was revealed in 19.0 %, in 15.4 % – cardiovascular diseases, in 13.7 % – diseases of the upper gastrointestinal tract. Diabetes mellitus was found in 4.6 % of patients, and obesity – in 5.9 %, kidney disease – 3.0 %. The remaining concomitant diseases occurred in less than 2.0 % of the observed patients. It has been established that diseases of the biliary tract and pancreas, gastrointestinal tract, diabetes mellitus, obesity, cardiovascular diseases are risk factors for the development of liver fibrosis in chronic HCV infection.Conclusions. The data obtained indicate the need for a more personalized approach to monitoring patients and the need to create integrated models of medical care for patients with chronic hepatitis C.

Download Full-text

P744 DEPDC5 GENE LOCUS ASSOCIATES WITH SEVERE LIVER FIBROSIS IN INDIVIDUALS WITH CHRONIC HCV INFECTION

Journal of Hepatology ◽

10.1016/s0168-8278(14)60905-3 ◽

2014 ◽

Vol 60 (1) ◽

pp. S318

Author(s):

M.A. Burza ◽

B.M. Motta ◽

A.L. Fracanzani ◽

A. Aghemo ◽

S. Fargion ◽

...

Keyword(s):

Liver Fibrosis ◽

Gene Locus ◽

Hcv Infection ◽

Severe Liver ◽

Chronic Hcv Infection ◽

Chronic Hcv

Download Full-text

Non-invasive methods for the diagnosis of liver fibrosis in chronic HCV-infection

Journal Infectology ◽

10.22625/2072-6732-2021-13-1-58-65 ◽

2021 ◽

Vol 13 (1) ◽

pp. 58-65

Author(s):

A. I. Fazul’zyanova ◽

A. K. Husainova ◽

S. V. Tkacheva ◽

F. M. Yakupova

Keyword(s):

Liver Cirrhosis ◽

Liver Fibrosis ◽

Antiviral Therapy ◽

Prognostic Significance ◽

Hcv Infection ◽

Direct Acting Antiviral ◽

Chronic Hcv Infection ◽

Chronic Hcv ◽

Direct Acting ◽

Severe Fibrosis

Objective: to study the values of fibrosis indices and transient elastometry in patients with chronic HCV infection who received antiviral therapy.Materials and methods: The study included 64 patients with chronic HCV infection who received antiviral therapy with direct-acting antiviral drugs or a combination of peginterferon and ribavirin.The fibrosis indices AAR, APRI and FIB-4 were calculated before the start of therapy and 6 months after its completion. Values of AAR>1, APRI≥1,5, and FIB-4≥1,45 were considered indicators of severe fibrosis. We studied the dynamics of fibrosis indices and elastometry values depending on the treatment regimen, their correlation and the prognostic significance of fibrosis indices in relation to elastometry.Results. Among patients treated with direct-acting antiviral drugs, a sustained virologic response was achieved in 100%, and peginterferon-containing regimen – in 85%. Elastometry and APRI and FIB-4 indices decreased in both groups. In patients without liver cirrhosis, the average elastometry after treatment decreased from 9,5±1,7 kPa to 6,7 ± 1.4 kPa (p = 0,0006). In patients with liver cirrhosis, the median of elastometry decreased from 20 to 11,7 kPa (p = 0,0006), the median of APRI decreased from 2,09 to 0,61 (p = 0,005), FIB-4 from 3,95 up to 2,22 (p = 0,022). The prognostic significance of FIB-4 in relation to elastometry before treatment was 81%, after – 82%.Conclusion. Successful etiotropic therapy leads to an improvement in values of liver fibrosis indices and transient elastometry in patients with HCV infection, including liver cirrhosis, regardless of the treatment regimen. The FIB-4 index showed the highest sensitivity and prognostic significance in determining severe fibrosis.

Download Full-text